文献速递造血干细胞移植与细胞治疗

HLA错配无关供者骨髓移植联合移植后环磷酰胺的多中心II期试验

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
PubMed 文献 · J Clin Oncol · 2021-04-27

National Marrow Donor Program资助的多中心II期研究评估HLA错配无关供者骨髓移植联合移植后环磷酰胺(PTCy)治疗血液系统恶性肿瘤的可行性。80例患者在11个美国移植中心入组,1年总生存率达76%(90% CI 67.3-83.3),达到主要终点;48%为少数族裔,提示该策略可扩大移植可及性。

要点

  • MMUD骨髓移植联合PTCy的1年OS为76%(90% CI 67.3-83.3),达到主要终点。
  • 48%入组患者为少数族裔,39%供受者对仅匹配4-6/8个HLA等位基因。
  • 与接受PTCy的其他错配移植对照相比,多因素分析示OS无显著差异。

核心结论

  • HLA错配无关供者骨髓移植联合PTCy在血液系统恶性肿瘤中可行且有效。
  • 近半数研究参与者为少数族裔,该策略可能显著扩大移植可及性。

研究设计与样本

  • 主要终点为1年总生存(OS),假设为65%或更优。

主要发现

  • 全队列1年OS为76%(90% CI 67.3-83.3),清髓性与减低强度预处理层分别为72%和79%。
  • 48%的患者为少数族裔,39%的供受者对匹配4-6/8个HLA等位基因。
  • 植入与移植物抗宿主病相关次要终点均达到。
  • 多因素分析比较研究组与其他错配移植对照,OS无显著差异。

关键数值与推荐

  • 预处理后第+3、+4天给予PTCy,第+5天起开始西罗莫司与吗替麦考酚酯。
  • 主要终点1年OS达76%(90% CI 67.3-83.3),超过65%的预设阈值。

临床怎么用

  • 对缺乏HLA全合无关供者的血液系统恶性肿瘤患者,可考虑MMUD骨髓移植联合PTCy。
  • 该策略尤其可能惠及少数族裔等HLA匹配供者匮乏人群。

局限性

  • 为单臂II期研究,样本量80例,与其他错配移植对照的比较非随机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT. PATIENTS AND METHODS: We performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy. RESULTS: Notably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS. CONCLUSION: Our prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021. PMID: 33905264. doi:10.1200/JCO.20.03502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。